Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host

Clinical Cancer Research

Volumn 16, Issue 14, 2010, Pages 3684-3695

  Tseng, William W ^a,b   Winer, Daniel ^a   Kenkel, Justin A ^a   Choi, Okmi ^a   Shain, Alan H ^a   Pollack, Jonathan R ^a   French, Randy ^c   Lowy, Andrew M ^c   Engleman, Edgar G ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 KINASE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER INVASION; CANCER MODEL; CARCINOMATOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; ENZYME INHIBITION; FEMALE; GENE MUTATION; GENOME ANALYSIS; GENOMICS; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LATENT PERIOD; LIVER METASTASIS; MACROPHAGE; METASTASIS; MONONUCLEAR CELL; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; SUPPRESSOR CELL; SURVIVAL RATE; T LYMPHOCYTE; TUMOR CELL;

ADENOCARCINOMA; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; IMMUNOCOMPETENCE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 77954742056     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2384     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Izeradjene K, Hingorani SR. Targets, trials, and travails in pancreas cancer. J Natl Compr Canc Netw 2007;5:1042-53.
3. Hotz HG, Reber HA, Hotz B, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas 2003;26:e89-98.
4. Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, Ellenhorn JD. An orthotopic in vivo model of human pancreatic cancer. Surgery 1999;126:562-7.
5. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007;26:373-400. (Pubitemid 350115102)
6. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007;194:S84-6.
7. Hotz HG, Reber HA, Hotz B, et al. An improved clinical model of orthotopic pancreatic cancer in immunocompetent Lewis rats. Pancreas 2001;22:113-21. (Pubitemid 32179164)
8. Abraham AT, Shah SR, Davidson BR. The HaP-T1 Syrian golden hamster pancreatic cancer model: cell implantation is better than tissue implantation. Pancreas 2004;29:320-3.
9. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
10. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83. (Pubitemid 40719130)
11. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72. (Pubitemid 41180205)
12. Kano MR, Bae Y, Iwata C, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci 2007;104:3460-5.
13. Melisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor β receptor type I, type II. dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008;7:829-40. (Pubitemid 351551036)
14. Leach SD. Mouse models of pancreatic cancer: the fur is finally flying! Cancer Cell 2004;5:7-11.
15. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17:3112-26. (Pubitemid 38040774)
16. Tinder TL, Subramani DB, Basu GD, et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 2008;181:3116-25.
17. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984;44:717-26.
18. Leiter EH, Malinoski FJ, Eppig JJ. An epithelial cell line with chronic polyoma infection established from a spontaneous mouse pancreatic adenocarcinoma. Cancer Res 1978;38:969-77.
19. Maletzki C, Linnebacher M, Kreikemeyer B, Emmrich J. Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 2008;57:483-91. (Pubitemid 351442532)
20. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
21. Bresalier RS, Hujanen ES, Raper SE, et al. An animal model for colon cancer metastasis: establishment and characterization of murine cell lines with enhanced liver-metastasizing ability. Cancer Res 1987;47:1398-406.
22. Kuo TH, Kubota T, Watanabe M, et al. Liver colonization competence governs colon cancer metastasis. Proc Natl Acad Sci U S A 1995;92:12085-9.
23. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49. (Pubitemid 43727584)
24. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008;68:2561-3. (Pubitemid 351556251)
25. Qin FX. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. Cell Mol Immunol 2009;6:3-13.
26. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
27. Mende I, Engleman EG. Breaking tolerance to tumors with dendritic cell-based immunotherapy. Ann N Y Acad Sci 2005;1058:96-104.
28. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52. (Pubitemid 39620069)
29. Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 2008;19:65-77. (Pubitemid 351200062)
30. Morse MA, Hall JR, Plate JM. Countering tumor-induced immuno-suppression during immunotherapy for pancreatic cancer. Expert Opin Biol Ther 2009;9:331-9.
31. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518-27. (Pubitemid 47535942)
32. Garbe AI, Vermeer B, Gamrekelashvili J, et al. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res 2006;66:508-16. (Pubitemid 43166060)